Last reviewed · How we verify
Immune Support (CORTISONE)
Immune Support, originally developed by Chartwell Molecular and currently owned by Merck, is a small molecule cortisone medication. It was FDA approved in 1974 for the treatment of cough, fever, headache, fatigue, coldness, muscle pain, sore throat, and ear congestion. The medication is off-patent, with 12 generic manufacturers available. Key safety considerations include the potential for corticosteroid-related side effects. Commercially, Immune Support is available as a generic medication.
At a glance
| Generic name | CORTISONE |
|---|---|
| Sponsor | Merck |
| Drug class | Non-Standardized Plant Allergenic Extract [EPC] |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
- cough
- fever
- headache
- fatigue
- coldness
- muscle pain
- sore throat
- ear congestion
- nose congestion
- throat congestion
Common side effects
Key clinical trials
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2,PHASE3)
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma (PHASE2)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immune Support CI brief — competitive landscape report
- Immune Support updates RSS · CI watch RSS
- Merck portfolio CI